Navigation
In Ecofactor, Inc. v. Google LLC., J. Moore, writing for a majority of the en banc court, found that the expert witness testimony of David Kennedy to be unreliable and therefore inadmissible. Stated the court:
The “whereas” recital of each license provides no indication that the licensees agreed to pay the $X rate or shared EcoFactor's belief that $X constituted a reasonable royalty. The licenses therefore do not, individually or in combination, provide support for Mr. Kennedy's testimony that the licensees agreed to pay the $X rate or that the licensees agreed that $X was a reasonable royalty. This analysis does not usurp the province of the jury, nor does it involve this court deciding disputes of fact. It involves the gatekeeping function of the court to ensure that there are sufficient facts or data for Mr. Kennedy's testimony that the licensees agreed to the $X royalty rate.“
Judges Reyna and Stark dissented in part, arguing:
The en banc court's sudden shift deprives EcoFactor of notice and opportunity to be heard, and avoids what this appeal is really about, i.e., the extent to which district courts have discretion to decide fact-based questions of admissibility under Rule 702 and Daubert. And after only finding fault with a narrow point of Mr. Kennedy's testimony on contract interpretation grounds, the en banc court appears to inexplicably rule that Mr. Kennedy's entire testimony should have been excluded.”
This criticism is answered in footnote 6 of the majority opinion, which sates, “The three licenses Mr. Kennedy interpreted are in fact contracts. The question presented focused on whether Mr. Kennedy's expert opinion about the interpretation of the licenses satisfies rule 702 and Daubert. Interpretation of the licenses is fairly included within the question presented.”
Oral arguments: Deriving a royalty rate from a lump sum payment amount
Oral Arguments: AI transcription
The Federal Circuit, en banc, held oral arguments in Ecofactor v. Google LLC. The case hinges on whether Ecofactor's damages expert, David Kennedy, relied on sufficient facts to support his conclusion of an “$X” “reasonable royalty rate,” based on lump-sum payment amounts cited in prior license deals. The prior license deals, in recitals, specified that the lump sum is based on a royalty rate, while in the body of the licenses, which relate to terms to which both parties agreed, states the opposite – i.e., that the lump sum is not related to a reasonable royalty rate.
In her arguments, Google's attorney summed it as follows: the approach challenged here allows experts to transform unilateral assertions in the recitals (which the licensee has little incentive to challenge) into authoritative expert testimony that the licensee actually agreed to a particular rate and that this “undermines the jury's ability to reach a fair apportionment verdicts.”
Procedural History
On this record, it’s impossible to establish that these lump-sum payments were calculated using any royalty rate, let alone the specific $X rate. The self-serving recitals reflect only EcoFactor’s transparent attempt to manufacture a royalty rate using its “belief.”
Blogs:
An increasing volume among patent professionals and USPTO watchers are sounding the alarm that the dismantling of the U.S. government has reached the Patent Office, with big changes occurring now and potentially bigger changes in the near future:
President Trump's pick to become the next Director of the USPTO, John Squires, wants to improve efficiency and produce “born strong” patents. At his Senate confirmation hearing on May 21, 2025, Squires stated:
That nearly 7 in 10 patents are defective. (A USPTO spokesperson told IP Watchdog that they were not sure where the number comes from.) That troll practices are exploitative of inventors. That PTAB is in need of reform.
In Recentive Analytics, Inc. v. Fox Corp. the Federal Circuit held that claims that do no more than apply established methods of machine learning to a new data environment are not patent eligible.
Recentive argued in its briefs that its application of machine learning is not generic because “Recentive worked out how to make the algorithms function dynamically. . . .” But the court held:
Even if Recentive had not conceded the lack of a technological improvement, neither the claims nor the specifications describe how such an improvement was accomplished. That is, the claims do not delineate steps through which the machine learning technology achieves an improvement.“
Patent Docs (linked below) notes that the Court hints that more detail in the claim and the specification regarding the technical improvement, such as the training process, could avoid a finding of ineligibility.
The USPTO implemented significant new and increased fees. Widespread fee increases of 5% or around 5% are included plus targeted fee adjustments in excess thereof. Below are some noteworthy fee adjustments and some new fees extracted from the announcement.
Description | % increase | Previously | New |
---|---|---|---|
Claims fees: | |||
Independent claims in excess of 3 | 25% | $480 | $600 |
Claims in excess of 20 | 100% | $100 | $200 |
Extensions of time: | |||
Extensions for response within the 1st month | -77% | $220 | $50 |
Extensions for response within the second month | -84% | $640 | $100 |
Extensions for response within the third month | -86% | $1,480 | $200 |
Patent term related: | |||
Filing an application for patent term adjustment | 43% | $210 | $300 |
Filing for an extension of patent term | 468% | $1,180 | $6,700 |
RCEs: | |||
1st RCE | 10% | $1,360 | $1,500 |
2nd RCE | 25% | $2,000 | $2,500 |
3rd RCE | 80% | $2,000 | $3,600 |
Terminal disclaimers: | |||
TD filed prior to 1st action on the merits | 18% | $170 | $200 |
TD filed prior to a final action or allowance | 194% | $170 | $500 |
TD filed after final or allowance | 371% | $170 | $800 |
Maintenance fees: | |||
Petititon for the delayed maintenance fee payment | 43% | $2,100 | $3,000 |
IPRs: | |||
IPR request | 25% | $19,000 | $23,750 |
IPR post-institution fee (up to 20 claims) | 25% | $22,500 | $28,125 |
Description | Amount |
---|---|
Consideration of AFCP 2.0 Request | $500 |
Filing an application or presentation of a benefit claim more than 5 years after earliest benefit date | $2,200 |
Filing an application or presentation of a benefit claim more than 8 years after earliest benefit date | $3,500 |
Filing an IDS causing a cumulative number of applicant-provided items to exceed 50 but not 100 | $200 |
Filing an IDS causing a cumulative number of applicant-provided items to exceed 100 but not 200 | $500 |
Filing an IDS causing a cumulative number of applicant-provided tiems to exceed 200 | $800 |
Request for Director review of PTAB decision | $440 |
The USPTO announced that, effective May 13, 2025, patents will grant in two weeks from the date of Issue Notification, down from a current processing time of an average of about three weeks.
In In re Riggs, the Federal Circuit vacated PTAB's assertion that a previously filed patent application qualifies as prior art based on the earlier filing of a provisional application. Stated the court: “to claim priority to the provisional filing date, the portion of the application relied on by the examiner as prior art must be supported by the provisional application.”
Kyle W. Kellar of Womble Bond Dickinson surveyed recent PTAB decisions post the rescission of Vidal's “Interim Guidelines” memorandum by the PTO regarding discretionary denials of IPR petitions. “In short, recission of the Interim Guidelines has had no impact, yet” according to Kellar.
Of the four discretionary denial decisions since the Interim Guidelines memo was rescinded, Kellar found the following results:
Name | Result | Rationale |
---|---|---|
Savant Technologies LLC v. Feit Electric Co., Inc. | IPR instituted | No trial date set, median time-to-trial statistics suggested a trial would likely occur well after a final written decision would issue. |
Mobileye Global, Inc. v. Facet Technology Corp. | IPR instituted | Fintiv factors considered without mention of Interim Guidelines |
Adobe Inc. v. Jaffe | IPR instituted | No trial date set |
Toyota Motor Corp. v. Emerging Automotive LLC | IPR denied | Petitioner failed to establish a reasonable likelihood that it would prevail. |
Kellar notes that the board “at least facially considered median time-to-trial statistics provided by the parties.”
Blogs:
In C. R. Bard Inc. v. Atrium Medical Corp.,1) the 9th Circuit found that a provision of a patent license, which requires a $3.75M minimum royalty payment until expiry of the last licensed patent, was not a violation of the Brulotte Rule. The Brulotte rule originates in the Supreme Court ruling Brulotte v. Thys Co., 379 U.S. 29 (1964), and held that patent holders may not contract for royalties on any use of a patented invention that occurs after the patent has expired.
Here, the 9th Circuit determined that the license agreement terms did not violate because the minimum royalty, which was the provision in dispute, was effectively creating a minimum royalty payment for the period that at least one of the U.S. and Canadian patents were in force. The Court explained that the Brulotte rule only concerns royalties for post-expiration use of a U.S. patent–it does not prohibit royalties that are for 'something other than the use of hte expired U.S. patent” which, in this case, is the still-unexpired Canadian patent.
In Fujifilm Corp. v. Kodak GmbH, before the Düsseldorf Local Division of the UPC, the court held that it has jurisdiction to render infringement and enforcement decisions implicating the UK, which is not a UPC or EU member state, because:
In Novartis Pharma. v. Torrent Pharma, the Fed. Cir. reversed the District of Delaware court's finding that the patent at issue failed to meet the written description requirement because it fails to describe the accused product which, while within the scope of the claims, includes improvements not mentioned in the patent. The court reasoned that, “A specification adequately describes an invention when it reasonably conveys . . . that the inventor had possession of the claimed subject matter as of the filing date.” The Fed. Cir. also uphold the lower court's finding that the claims were enabled because “enablement is judged as of the priority date.”
In Omni Medsci, Inc. v. Apple Inc. (Aug. 2, 2021), the Federal Circuit held that an employment agreement stating “Patents . . . acquired as a result of or in connection with . . . research, or other educational activities conducted by members of the University staff . . . shall be the property of the University.” The majority opinion (with J. Newman dissenting) concluded that the language “is most naturally read as a statement of intended disposition and promise of a potential future assignment, not as a present automatic transfer.
In J. Newman's dissent, she finds:
This ruling is not correct as a matter of contract interpretation, and overturns decades of unchallenged understanding and implementation of the University's employment agreement and policy documents. Omni does not own these patents and does not have standing to sue for infringement.
J. Newman notes that “the plain meaning of 'shall be the property of the University' is that the inventions made during employment and patents thereon shall belong to the University. [. . .] According to my colleagues, this fatal flaw . . . could have been avoided simply by using the present tense 'is the property of the University' instead of the future tense 'shall be the property of the University.' However, these documents necessarily apply only to future inventions, for which the future tense is appropriate.”
35 U.S.C. § 287(a): ”[. . .] In the event of failure so to mark, no damages shall be recovered by the patentee in any action for infringement, except on proof that the infringer was notified of the infringement and continued to infringe thereafter, in which event damages may be recovered only for infringement occurring after such notice.“
In Lighting Defense Group LLC v. Shanghai Sensi Electronic Engineering Co. Ltd. et al. 2), the failure of a licensed third party to mark products as patented triggered 35 U.S.C. § 287. LDG licensed its patent in May of 2020 and argued that opposing party SANSI was liable for infringement prior to that date, i.e., prior any legal requirement to mark. Based on the plain meaning of the statute, the court disagreed.
Stated the court:
Generally, a patentee who never makes or sells a patented article does not trigger § 287's requirements. However, the federal Circuit has expounded, '[. . .] If, however, a patentee makes or sells a patented article and fails to mark in accordance with § 287, the patentee cannot collect damages until it either begins providing notice or sues the alleged infringer . . . and then only for the period after notification or suit has occurred.' SANSI asks the Court to join its sister court in holding that failure to comply with the marking requirements after attachment cuts off all pre-notice damages, not just those arising after, as consistent with Arctic Cat II. LDG asks the Court to reject those cases and follow Arendi's, where the Delaware district court concluded Arctic Cat II does not preclude recovery of damages for periods before the marking obligation attached.
[. . .]
Under a plain reading, § 287(a) precludes recovery after the requirement to mark is triggered until actual notice is given, after which that date then controls the starting date for recovery. Although this is a harsh result, the plain language controls.
In 2024, the Federal Circuit issued eighteen opinions labeled “precedential” that were related to patent law. Quotations below omit citations and internal quotation marks. Here is a break-down:
Cytiva Bioprocess R&D AB v. JSR Corp.: Non-obviousness of novel compounds
Holdings:
Palo Alto Networks, Inc. v. Centripetal Networks, LLC et al.: Motivation to combine (Patent challenger appeals from unsuccessful IPR.)
Pfizer Inc. v. Sanofi Pasteur Inc.: Optimization of result-effective variables (Patent owner Pfizer challenges IPR holding of invalidity.)
Holdings:
Virtek Vision Internat'l ULC v. Assembly Guidance Systems, Inc.: Motivation (Patent owner Virtek and patent challenger Aligned Vision cross-appeals IPR findings of a subset of challenged claims invalid.)
Holdings:
Sanho Corp. v. Kaijet Tech. Int'l Ltd.: Excluding prior art under § 102(b)(2)(B) (Patent owner Sanho appeals invalidity finding by PTAB.)
35 U.S.C. § 102(b)(2): A disclosure shall not be prior art to a claimed invention under subsection (a)(2) if–
(B) the subject matter disclosed had, before such subject matter was effectively filed under subsection (a)(2), been publicly disclosed by the inventor or a joint inventor or another who obtained the subject matter disclosed directly or indirectly from the inventor or a joint inventor.
Holdings:
Weber v. Provisur Tech.: Printed publication requirement. (Patent challenger Weber appeals PTAB holding that Provisur's patents were not invalid.)
Holdings:
LKQ Corp. v. GM Global Tech. Operations, LLC: Design Patent Nonobviousness (Patent challenger LKQ appeals PTAB decision upholding GM's design patent on a vehicle front fender.)
Holdings: “We conclude that the Rosen-Durling test requirements—that (1) the primary reference be “basically the same” as the challenged design claim; and (2) any secondary references be “so related” to the primary reference that features in one would suggest application of those features to the other—are improperly rigid. The statutory rubric along with Supreme Court precedent including Whitman Saddle, Graham, and KSR, all suggest a more flexible approach than the Rosen-Durling test when determining obviousness.”
IOENGINE, LLC v. Ingenico Inc.: Printed matter doctrine (Fed. Cir. reversed PTAB's invalidation of claims related to portable data processing devices.)
Exemplary claim:
Claim 2: Code . . . configured to cause a communication to be transmitted to the . . . node
Claim 4: Wherein the communication caused to be transmitted to the . . . node facilitates transmission of encrypted communications from the . . . node to the terminal.”
Holdings:
Pacific Biosciences of California, Inc. v. Personal Genomics Taiwan, Inc.: “For identifying a single biomolecule”
Claim 1. An apparatus for identifying a single biomolecule, comprising:
a substrate having a light detector; and
a linker site formed over the light detector, the linker site being treated to affix the biomolecule to the linker site;
wherein the linker site is proximate to the light detector and is spaced apart from the light detector by a distance of less than or equal to 100 micrometers.
Holdings:
RAI Strategic Holdings v. Philip Morris Products: Claimed ranges (Appeal by patent owner RAI of post-grant review finding invalidity.)
ZyXEL Communications v. Unm Rainforest Innovations: Motion to Amend [MTA] Pilot Program. (ZyXEL appeals PTAB's grant to UNMRI's motion to amend and finding claim 8 nonobvious; UNMRI cross-appeals on other findings.)
37 C.F.R. § 42.121(b): A motion to amend claims must include a claim listing . . . and set forth: (1) The support in the original disclosure of the patent for each claim that is added or amended; and (2) The support in an earlier-filed disclosure for each claim for which benefit of the filing date of the earlier filed disclosure is sought.
SoftView LLC v. Apple Inc.: Estoppel (Patent owner SoftView appeals PTAB invalidation of all claims based on estoppel)
37 C.F.R. § 42.73(d)(3): A patent applicant or owner is precluded from taking action inconsistent with the adverse judgment, including obtaining in any patent: (i) A claim that is not patentably distinct from a finally refused or canceled claim.
Holdings:
Cywee Group Ltd. v. ZTE (USA), Inc.: Joint IPR petitioners (Patent owner Cywee appeals IPR decision holding original and proposed amended claims unpatentable.)
Holdings:
Koss Corp. v. Bose Corp.: Mootness/Issue Preclusion
Holdings:
Platinum Optics Tech. v. Viavi Solutions: Standing (Patent challenger PTOT appeals a final written decision from IPR.)
Holdings:
Speck v. Bates: Interference - (Junior party Speck appeals PTAB's decision awarding priority to Bates.)
37 C.F.R. § 135(b)(1): A claim which is the same as, or for the same or substantially the same subject matter as, a claim of an issued patent may not be made in any application unless such a claim is made prior to one year from the date on which the patent was granted.
Holdings:
Voice Tech v. Unified Patents: Appealing after Request for Rehearing (Patent owner Voice Tech appeals from PTAB finding all challenged claims obvious.)
Google LLC v. EcoFactor, Inc.: Claim construction and APA (Fed. Cir. vacated PTAB's claim construction.)
Pfizer Inc. v. Sanofi Pasteur Inc.: Director Review (Patent owner Pfizer challenges IPR holding of invalidity.)
Additional blurbs are accessible in categorized lists by accessing the Index link on the left (or, for small-format screens, below).